BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

- PDUFA target action date of May 8, 2027

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.